Tibet Duo Rui Pharmaceutical Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 3/6
Tibet Duo Rui Pharmaceutical has a total shareholder equity of CN¥766.1M and total debt of CN¥236.7M, which brings its debt-to-equity ratio to 30.9%. Its total assets and total liabilities are CN¥1.1B and CN¥303.9M respectively.
Anahtar bilgiler
30.9%
Borç/özkaynak oranı
CN¥236.69m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | CN¥396.93m |
| Eşitlik | CN¥766.15m |
| Toplam yükümlülükler | CN¥303.86m |
| Toplam varlıklar | CN¥1.07b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
What Tibet Duo Rui Pharmaceutical Co., Ltd.'s (SZSE:301075) 41% Share Price Gain Is Not Telling You
Oct 09
Tibet Duo Rui Pharmaceutical's (SZSE:301075) Solid Earnings May Rest On Weak Foundations
May 01Tibet Duo Rui Pharmaceutical Co.,Ltd. (SZSE:301075) Stock Rockets 44% As Investors Are Less Pessimistic Than Expected
Mar 08Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 301075's short term assets (CN¥615.3M) exceed its short term liabilities (CN¥133.6M).
Uzun Vadeli Yükümlülükler: 301075's short term assets (CN¥615.3M) exceed its long term liabilities (CN¥170.2M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 301075 has more cash than its total debt.
Borcun Azaltılması: 301075's debt to equity ratio has increased from 20% to 30.9% over the past 5 years.
Borç Kapsamı: 301075's operating cash flow is negative, therefore debt is not well covered.
Faiz Kapsamı: Insufficient data to determine if 301075's interest payments on its debt are well covered by EBIT.